Moderna Inc said on Monday it has applied for US emergency authorization for its COVID-19 vaccine after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns.

Moderna, which also plans to seek European approval, reported that its vaccine's efficacy was consistent across age, race, ethnicity and gender demographics as well as having 100% success in preventing severe cases of the disease that has killed nearly 1.5 million people worldwide.